Rama Nadella, MD
Neurology · Huntsville, ALNPI 1124072145
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $917 and has fallen 86.6% since, to $123 in 2025. That places this record below the midpoint for neurology clinicians in AL, where the typical reported total is $2,219.
Across 21 payments — averaging $59.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$186
- Avanir Pharmaceuticals, Inc.$148
- Grifols USA, LLC$142
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$127
- EMD Serono, Inc.$125
- Boehringer Ingelheim$125
- plus $407 from 9 others
Across 2 payments — averaging $849.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$2K
What the payments were for
- Food & beverage$1,258100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 2 | $186 |
| Avanir Pharmaceuticals, Inc. | 3 | $148 |
| Grifols USA, LLC | 1 | $142 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $127 |
| EMD Serono, Inc. | 1 | $125 |
| Boehringer Ingelheim | 1 | $125 |
| Teva Pharmaceuticals USA, Inc. | 1 | $111 |
| UCB, Inc. | 1 | $106 |
| Biogen | 3 | $55 |
| Novartis | 2 | $45 |
| Natus Medical Incorporated | 1 | $29 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| Livanova USA, Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
| Amgen | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,258 in reported general payments places this provider in the 40th percentile of 255 neurology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Huntsville
- Harry McDarisHuntsville$307K
- Belinda Savage-EdwardsHuntsville$296K
- Anjaneyulu AlapatiHuntsville$133K
- Bhageeradh MulpurHuntsville$74K
- David GreerHuntsville$67K
- Scott HitchcockHuntsville$41K
- David WhiteHuntsville$40K
- Amit AroraHuntsville$22K
- Jitesh KarHuntsville$18K
- Diane CounceBirmingham$895K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.